Analysts’ Viewpoint on Global Nonalcoholic Steatohepatitis Therapeutics Market Scenario
As there is no FDA-approved drug to treat nonalcoholic steatohepatitis, pharmaceutical companies and market stakeholders are expected to launch pipeline drugs to cure this silent liver disease. The global nonalcoholic steatohepatitis therapeutics market is driven by increase in global prevalence rate of diabetic and obesity, along with rise in awareness about the treatments and drugs available for the same. Moreover, in order to boost credibility credentials, manufacturers are engaging in clinical trials of Elafibranor and various other drugs that help in reducing fat percentage in liver. Market stakeholders should focus on mergers & acquisitions and research collaborations with other companies to launch innovative products for the effective treatment of nonalcoholic steatohepatitis in the upcoming years.
Nonalcoholic fatty liver disease (NAFLD) is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified; however, obesity and insulin resistance are believed to play major roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its functions.
NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis (NASH), a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time. Over a period of ten years, up to 20% of patients with NASH develop cirrhosis of the liver, and 10% succumb from the disease.
Presently, NASH is one of the leading causes of liver transplants in the U.S., with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are considered the leading cause of liver disease in countries in the West. Hence, there is an urgent need of effective treatment options for these diseases. This is expected to propel the nonalcoholic steatohepatitis therapeutics market over the next years.
Nonalcoholic steatohepatitis is a type of liver disease diagnosed in people who are non-alcoholic or consume alcohol in very low amount. Nonalcoholic steatohepatitis (NASH) is one of the commonly diagnosed liver diseases. The disease is also known as silent liver disease. Fat deposition in liver, along with inflammation is one of the significant conditions that occurs during the disease. The surge in the incidence rate of nonalcoholic steatohepatitis has increased the demand for therapeutics to treat the disease. Consequently, multiple drugs are being launched. These drugs aim to provide relief from the disease.
According to market analysts, the global nonalcoholic steatohepatitis therapeutics market is anticipated to witness double digit growth in the next few years. Increase in awareness among people about therapeutics is also a major factor boosting the growth of the market in various regions across the world. However, poor diagnostics and lack of proper diagnostic technique are projected to restrain the global market in the next few years.
Increase in research & development investments by pharmaceutical companies has led to seamless integration or multifunctional outsourcing solutions for drug research & development from the early development phase through the late-stage design phase. Outsourcing has grown as a strategic solution to offset the shortage of in-house resources necessary for product innovation, as pharma businesses face massive pressure to minimize operating expenses. Key pharmaceutical corporations are shifting to a simpler business strategy that primarily depends on outsourcing.
Majority of pharmaceutical companies outsource their testing facilities throughout research and development to increase profit margins, meet drug discovery timeframes, and save money.
The number of patients suffering from nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is high across the globe. However, the number increases in developed economies such as North America. This provides significant opportunities to companies and research centers looking to invest in the market. Moreover, the number of children suffering from obesity has nearly tripled in the past few years. This requires urgent treatment methods to keep a check and cure the disease in its initial stages.
People in the U.S. also suffer from high cholesterol levels. There is no exact cure for the disease; however, treatment is still being developed and worked upon. Moreover, advancements in technology and continuous efforts by research firms to develop a more effective treatment method to drive the global nonalcoholic steatohepatitis therapeutics market.
The etiology of COVID-19 liver injury can be related to various reasons, including virus-induced inflammatory responses, hepatic obstruction, hypoxia, and drug-induced liver problems. Coronavirus has been linked to hepatic damage and liver-related fatality in cirrhotic individuals. The impact of COVID-19 on health services has had a negative influence on the care of delivery and the prognosis of patients with chronic liver disease. Consequently, there has been a drop in the therapy, detection, and follow-up of individuals with liver problems, which has had a severe effect on the healthcare industry. Additionally, drug clinical trials have stalled since most corporations have postponed the launch of newest studies in various nations.
The global nonalcoholic steatohepatitis therapeutics market has been segmented based on drug type into potential phase III candidates obeticholic acid (OCA), Aramchol, Saroglitazar, and Elafibranor. Moreover, the report provides a list of candidates in phase I and phase II clinical trials. Elafibranor is expected to account for a key share of the global market during the forecast period, followed by Obeticholic Acid (OCA). The Elafibranor segment is expected to grow at the highest CAGR from 2022 to 2031.
Elafibranor has the capability to reduce fat substance of liver and has demonstrated positive impact during phase 3 clinical trials. This progress of the clinical trial has helped in the likelihood of commercialization of Elafibranor. Elafibranor has better prospects in the market, as there is no medicine available for the treatment of NASH.
Governments in both rich and emerging economies are advocating cost-cutting initiatives such as lowering prescription coverage costs and increasing the usage of generic medications. Governments, insurers, and individuals are putting substantial cost-cutting pressure on drug makers globally. This leads to increase in medication acceptance in developing countries, where there is a considerable need of low-cost treatments. This, however, has a negative effect on the performance of various pharmaceutical businesses. This trend is likely to continue during the forecast period, owing to the ongoing demand from insurers and lowering of pharma pricing by personal & corporate payers due to worries about providing more innovative drugs to treat prevalent ailments.
In terms of region, the global nonalcoholic steatohepatitis therapeutics market has been segmented into North America, Asia Pacific, Europe, Latin America, Middle East & Africa. North America dominated the global market, accounting for key share in 2021.
North America is significantly affected by NASH due to rise in population suffering from diabetes and obesity. Moreover, prevailing cases of high cholesterol and changes in lifestyle make North America an attractive market for future development and growth.
In Europe, countries such as Italy, Spain, Germany, the U.K., and France are the main areas with high prevalence of NASH. These countries are likely to be highly lucrative markets for nonalcoholic steatohepatitis therapeutics.
This report profiles key players in the global nonalcoholic steatohepatitis therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nonalcoholic steatohepatitis therapeutics market is highly fragmented, with the presence of a number of international as well as regional players. Leading players operating in the global nonalcoholic steatohepatitis therapeutics market are Intercept Pharmaceuticals, Inc., GENFIT SA, Zydus Cadila, Conatus Pharmaceuticals, and Tobira Therapeutics, Inc., AstraZeneca plc, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., and Immuron Ltd., among others.
The report on the global nonalcoholic steatohepatitis therapeutics market discusses individual strategies, followed by company profiles of manufacturers of the nonalcoholic steatohepatitis therapeutics market products. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global nonalcoholic steatohepatitis therapeutics market.
Key players in the global nonalcoholic steatohepatitis therapeutics market are growing their market presence by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market position across the world. Key developments in the global nonalcoholic steatohepatitis therapeutics market include:
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 10.1 Bn |
|
Market Forecast Value in 2031 |
US$ 20.2 Bn |
|
Growth Rate (CAGR) |
13.6% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global nonalcoholic steatohepatitis therapeutics market was valued at US$ 10.1 Bn in 2021.
The global nonalcoholic steatohepatitis therapeutics market will surpass US$ 13.6 Bn by 2031.
Surge in number of nonalcoholic steatohepatitis incidence and increase in cases of diabetes & obesity propel demand and positively impact the global market.
North America is expected to be a potential revenue generator for vendors during the forecast period.
Prominent players in the global nonalcoholic steatohepatitis therapeutics market include Intercept Pharmaceuticals, Inc., GENFIT SA, Zydus Cadila, Conatus Pharmaceuticals, and Tobira Therapeutics, Inc., AstraZeneca plc, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., and Immuron Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nonalcoholic Steatohepatitis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Product/ Brand Analysis
5.2. Key industry events (mergers, acquisitions, product launches etc.)
5.3. Technological Advancements
5.4. Regulatory Scenario, by Region/ Globally
5.5. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Obeticholic Acid (OCA)
6.3.2. Aramchol (arachidyl amido cholanoic acid)
6.3.3. Saroglitazar
6.3.4. Elafibranor
6.4. Market Attractiveness By Drug Type
7. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Drug Type, 2017–2031
8.2.1. Obeticholic Acid (OCA)
8.2.2. Aramchol (arachidyl amido cholanoic acid)
8.2.3. Saroglitazar
8.2.4. Elafibranor
8.3. Market Value Forecast, by Country, 2017–2031
8.3.1. U.S.
8.3.2. Canada
8.4. Market Attractiveness Analysis
8.4.1. By Drug Type
8.4.2. By Country
9. Europe Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Type, 2017–2031
9.2.1. Obeticholic Acid (OCA)
9.2.2. Aramchol (arachidyl amido cholanoic acid)
9.2.3. Saroglitazar
9.2.4. Elafibranor
9.3. Market Value Forecast, by Country/Sub-region, 2017–2031
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Market Attractiveness Analysis
9.4.1. By Drug Type
9.4.2. By Country/Sub-region
10. Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Obeticholic Acid (OCA)
10.2.2. Aramchol (arachidyl amido cholanoic acid)
10.2.3. Saroglitazar
10.2.4. Elafibranor
10.3. Market Value Forecast, by Country/Sub-region, 2017–2031
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia & New Zealand
10.3.5. Rest of Asia Pacific
10.4. Market Attractiveness Analysis
10.4.1. By Drug Type
10.4.2. By Country/Sub-region
11. Latin America Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Obeticholic Acid (OCA)
11.2.2. Aramchol (arachidyl amido cholanoic acid)
11.2.3. Saroglitazar
11.2.4. Elafibranor
11.3. Market Value Forecast, by Country/Sub-region, 2017–2031
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Market Attractiveness Analysis
11.4.1. By Drug Type
11.4.2. By Country/Sub-region
12. Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Obeticholic Acid (OCA)
12.2.2. Aramchol (arachidyl amido cholanoic acid)
12.2.3. Saroglitazar
12.2.4. Elafibranor
12.3. Market Value Forecast, by Country/Sub-region, 2017–2031
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East & Africa
12.4. Market Attractiveness Analysis
12.4.1. By Drug Type
12.4.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player - Competition Matrix (by tier and size of companies)
13.2. Market Share Analysis By Company (2021)
13.3. Company Profiles
13.3.1. F. Hoffmann-La Roche
13.3.1.1. Company Overview (HQ, Business Segments, Employee)
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Strategic Overview
13.3.2. Siemens Healthineers AG.
13.3.2.1. Company Overview (HQ, Business Segments, Employee)
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Strategic Overview
13.3.3. Thermo Fisher Scientific
13.3.3.1. Company Overview (HQ, Business Segments, Employee)
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Strategic Overview
13.3.4. Danaher Corporation
13.3.4.1. Company Overview (HQ, Business Segments, Employee)
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Strategic Overview
13.3.5. Bio-Rad Laboratories
13.3.5.1. Company Overview (HQ, Business Segments, Employee)
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Strategic Overview
13.3.6. Abbott Laboratories
13.3.6.1. Company Overview (HQ, Business Segments, Employee)
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Strategic Overview
13.3.7. Alpco
13.3.7.1. Company Overview (HQ, Business Segments, Employee)
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Strategic Overview
13.3.8. Beckman Coulter Inc.
13.3.8.1. Company Overview (HQ, Business Segments, Employee)
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Strategic Overview
13.3.9. Chromsystems Instrume
13.3.9.1. Company Overview (HQ, Business Segments, Employee)
13.3.9.2. Product Portfolio
13.3.9.3. SWOT Analysis
13.3.9.4. Strategic Overview
13.3.10. Pharmaceutical Drug Type Development LLC
13.3.10.1. Company Overview (HQ, Business Segments, Employee)
13.3.10.2. Product Portfolio
13.3.10.3. SWOT Analysis
13.3.10.4. Strategic Overview
13.3.11. Randox Laboratories Ltd.
13.3.11.1. Company Overview (HQ, Business Segments, Employee)
13.3.11.2. Product Portfolio
13.3.11.3. SWOT Analysis
13.3.11.4. Strategic Overview
13.3.12. Other prominent players
13.3.12.1. Company Overview (HQ, Business Segments, Employee)
13.3.12.2. Product Portfolio
13.3.12.3. SWOT Analysis
13.3.12.4. Strategic Overview
List of Tables
Table 01: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 02: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Region, 2017-2031
Table 03: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country, 2017-2031
Table 04: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Table 05: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
Table 06: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Table 07: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
Table 08: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Table 09: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
Table 10: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Table 11: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
Table 12: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
List of Figures
Figure 01: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
Figure 02: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Region, 2017-2031
Figure 03: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country, 2017-2031
Figure 04: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Figure 05: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
Figure 06: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Figure 07: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
Figure 08: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Figure 09: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
Figure 10: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Figure 11: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031
Figure 12: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031
Figure 13: Global Nonalcoholic Steatohepatitis Therapeutics Market Share Analysis, by Company (2021)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Nonalcoholic Steatohepatitis Therapeutics Market
